IntelliGenome names ILEX South Africa as exclusive distributor for its CRISPR‑TB diagnostic in South Africa
Executive summary: IntelliGenome appointed ILEX South Africa as the exclusive distributor for CRISPR‑TB® in South Africa. The partnership opens a direct sales route into one of the world’s largest tuberculosis markets, which could increase diagnostic uptake and generate early‑stage revenue for IntelliGenome.
Who is involved: IntelliGenome (biotechnology firm) and ILEX South Africa (Pty) Ltd (distributor).
Likely next: ILEX South Africa will begin distributing CRISPR‑TB kits through its existing sales network to healthcare providers in South Africa.
IntelliGenome, a developer of CRISPR‑based molecular diagnostics, announced on July 20, 2026 that ILEX South Africa (Pty) Ltd will have sole rights to sell CRISPR‑TB® in the country. The deal gives IntelliGenome a dedicated channel into a high‑burden tuberculosis market, potentially accelerating test adoption and creating a new revenue stream. ILEX South Africa gains an exclusive product to add to its diagnostics portfolio, strengthening its position in the regional healthcare supply chain.
Timeline
- — IntelliGenome Appoints ILEX South Africa as Exclusive Distributor for CRISPR-TB (PR Newswire)
Analysis — what this means
Sectors affected
- TB molecular diagnostics